Emergency Medical Minute

Auteur(s): Emergency Medical Minute
  • Résumé

  • Our near daily podcasts move quickly to reflect current events, are inspired by real patient care, and speak to the true nature of what it’s like to work in the Emergency Room or Pre-Hospital Setting. Each medical minute is recorded in a real emergency department, by the emergency physician or clinical pharmacist on duty – the ER is our studio and everything is live.
    Copyright Emergency Medical Minute 2021
    Voir plus Voir moins
Épisodes
  • Episode 944: Colchicine Overdose
    Feb 17 2025

    Contributor: Aaron Lessen, MD

    Educational Pearls:

    • Colchicine is most commonly used for the prevention and treatment of gout

      • There is research investigating the anti-inflammatory and cardioprotective effects of colchicine

    • This drug has a narrow therapeutic index: a small margin between effective dose and toxic dose

    • Colchicine overdoses can be unintentional or intentional and are associated with poor outcomes

      • Phase 1: 10 - 24 hours after ingestion

        • Patient looks well but may have mild symptoms mimicking gastroenteritis

      • Phase 2: 24 hours - 7 days after ingestion

        • Multiple organ dysfunction syndrome (MODS)

      • Phase 3: recovery is usually within a few weeks of ingestion

    • Treatment for colchicine overdose

      • Treat early and aggressively

        • Gastrointestinal decontamination with activated charcoal and orogastric lavage

        • Dialysis and ECMO for MODS treatment

    References

    1. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348. PMID: 20586571.

    2. Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol. 2015;11(11):1781-94. doi: 10.1517/17425255.2015.1076391. Epub 2015 Aug 4. PMID: 26239119.

    Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3

    Donate: https://emergencymedicalminute.org/donate/

    Voir plus Voir moins
    3 min
  • Episode 943: Portal Vein Thrombosis
    Feb 10 2025

    Contributor: Travis Barlock, MD

    Educational Pearls:

    What is Portal Vein Thrombosis?

    • The formation of a blood clot within the portal vein, which carries blood from the gastrointestinal tract, pancreas, and spleen to the liver

    • Not only can this cause problems downstream in the liver, but the backup of venous blood can cause ischemia in the bowels

    How does it present?

    • Similar to acute mesenteric ischemia: Sudden onset of abdominal pain, nausea, vomiting, and fever

    How is it diagnosed?

    • Abdominal CT or MRI with contrast

    What causes it?

    • Cirrhosis

    • Coagulopathy (Factor V Leiden mutation, Prothrombin gene mutation, Antiphospholipid syndrome, Protein C, protein S, antithrombin III deficiency, etc.)

    • Oral Contraceptive Pills (OCPs)

    • Cancer such as hepatocellular carcinoma

    How is it treated?

    • Aggressive fluid resuscitation

    • Antibiotics. Be sure to cover enteric gram-negative bacteria and anaerobes

    • Heparin, same dosing as a bolus for a DVT

    • Endovascular treatment, such as a thrombectomy with IR

    • Surgical evaluation if there has been tissue death in the mesentery

    References

    • Hilscher, M. B., Wysokinski, W. E., Andrews, J. C., Simonetto, D. A., Law, R. J., & Kamath, P. S. (2024). Portal Vein Thrombosis in the Setting of Cirrhosis: Evaluation and Management Strategies. Gastroenterology, 167(4), 664–672. https://doi.org/10.1053/j.gastro.2024.05.017

    • Intagliata, N. M., Caldwell, S. H., & Tripodi, A. (2019). Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology, 156(6), 1582–1599.e1. https://doi.org/10.1053/j.gastro.2019.01.265

    • Ju, C., Li, X., Gadani, S., Kapoor, B., & Partovi, S. (2022). Portal Vein Thrombosis: Diagnosis and Endovascular Management. Pfortaderthrombose: Diagnose und endovaskuläres Management. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 194(2), 169–180. https://doi.org/10.1055/a-1642-0990

    Summarized by Jeffrey Olson MS3 | Edited by Jorge Chalit, OMS3

    Donate: https://emergencymedicalminute.org/donate/

    Voir plus Voir moins
    3 min
  • Episode 942: Acute Mountain Sickness and High Altitude Cerebral Edema
    Feb 3 2025

    Contributor: Jorge Chalit-Hernandez, OMS3

    Educational Pearls:

    • Acute mountain sickness (AMS) is the term given to what is otherwise colloquially known as altitude sickness

    • High altitude cerebral edema (HACE) is a severe form of AMS marked by encephalopathic changes

    • Symptoms begin at elevations as low as 6500 feet above sea level for people who ascend rapidly

      • May develop more severe symptoms at higher altitudes

    • The pathophysiology involves cerebral vasodilation

      • Occurs in everyone ascending to high altitudes but is more pronounces in those that develop symptoms

      • The reduced partial pressure of oxygen induces hypoxic vasodilation in the brain, which results in edema and, ultimately, HACE in some patients

    • Symptomatic presentation

      • Headache, nausea, and sleeping difficulties occur within 2-24 hours of arrival at altitude

      • HACE may occur between 12-72 hours after AMS and presents with ataxia, confusion, irritability, and ultimately results in coma if left untreated

    • Clinical presentation may be mistaken for simple exhaustion, so clinicians should maintain a high index of suspicion

      • Notably, if symptoms occur more than 2 days after arrival at altitude, clinicians should seek an alternative diagnosis but maintain AMS/HACE on the differential

    • Treatment and management

      • AMS

        • Adjunctive oxygen and descent to lower altitude

        • Acetazolamide is used as a preventive measure but is not helpful in acute treatment

        • +/- dexamethasone

      • HACE

        • Patients with HACE should receive dexamethasone to help reduce cerebral edema

        • Immediate descent to a lower altitude

    References

    1. Burtscher M, Wille M, Menz V, Faulhaber M, Gatterer H. Symptom progression in acute mountain sickness during a 12-hour exposure to normobaric hypoxia equivalent to 4500 m. High Alt Med Biol. 2014;15(4):446-451. doi:10.1089/ham.2014.1039

    2. Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med. 1989;321(25):1707-1713. doi:10.1056/NEJM198912213212504

    3. Luks AM, Beidleman BA, Freer L, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update. Wilderness Environ Med. 2024;35(1_suppl):2S-19S. doi:10.1016/j.wem.2023.05.013

    Summarized & Edited by Jorge Chalit, OMS3

    Donate: https://emergencymedicalminute.org/donate/

    Voir plus Voir moins
    4 min

Ce que les auditeurs disent de Emergency Medical Minute

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.